Zobrazeno 1 - 10
of 99
pro vyhledávání: '"L Gleich"'
Publikováno v:
Continence, Vol 7, Iss , Pp 100928- (2023)
Externí odkaz:
https://doaj.org/article/f447ea0294d34aa68c281b475e6d1d1d
Publikováno v:
Continence, Vol 7, Iss , Pp 100936- (2023)
Externí odkaz:
https://doaj.org/article/bb8d8c8ddfd44564a8b47c818a8f5594
Publikováno v:
Continence, Vol 7, Iss , Pp 101016- (2023)
Externí odkaz:
https://doaj.org/article/0aba397f48e645d39ed56c0dbf285272
Publikováno v:
Continence, Vol 7, Iss , Pp 100763- (2023)
Externí odkaz:
https://doaj.org/article/acd14a5cbbac4582ab7f89610b6e50e0
Autor:
Sibel Blau, Julio Antonio Peguero, Halle C. F. Moore, Ian Churchill Anderson, Minal A. Barve, Mathew Amprayil Cherian, Ahmed Elkhanany, Ciara Catherine Maria O'Sullivan, Alvaro Moreno-Aspitia, Paul Plourde, Lyon L. Gleich, Kendra Riesen, Ross Ezzati, Meghan Degele, Megan Shulman, Stephanie Stempf, Matthew M. Cooney, Senthil Damodaran
Publikováno v:
Journal of Clinical Oncology. 40:1504-1504
1504 Background: Trial recruitment that requires specific actionable mutations based on next-generation sequencing (NGS) is challenging. Barriers can include competing studies, physician study awareness, site proximity, mutation incidence, among othe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::36d445d64791bade7c20064e6f494507
https://doi.org/10.1200/jco.2022.40.16_suppl.1504
https://doi.org/10.1200/jco.2022.40.16_suppl.1504
Autor:
Jacob Stephen Thomas, Gary Gene Chiang, Stephen Theodore Worland, Rachel E. Sanborn, Kerry Pulver, Robert Sikorski, Nishan Tchekmedyian, Anthony B. El-Khoueiry, Lyon L. Gleich, Julio Antonio Peguero, Mark Densel, Neil Sankar, Vikas Dembla
Publikováno v:
Journal of Clinical Oncology. 38:3112-3112
3112 Background: Despite the broad activity of checkpoint inhibitors across tumor types, primary or secondary resistance after initial response represents a major challenge. Tomivosertib (T), a potent and highly selective inhibitor of the immunosuppr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a9ba97fa87e4e880090e13fd0163fbd8
https://doi.org/10.1200/jco.2020.38.15_suppl.3112
https://doi.org/10.1200/jco.2020.38.15_suppl.3112
Autor:
Annie Claude Benichou, Monica M. Mita, John Sarantopoulos, Adam Craig, Lyon L. Gleich, Alain C. Mita, Joe Stephenson, John Nemunaitis, Swami Padmanabhan-Iyer, Nisha Nanda
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Omacetaxine mepesuccinate is a first-in-class cephalotaxine demonstrating clinical activity in chronic myeloid leukemia. A subcutaneous (SC) formulation demonstrated efficacy and safety in phase 1/2 trials in patients previously treated with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25cbdcad70dfe3781060374f162510ae
https://doi.org/10.1007/s00280-012-1963-2
https://doi.org/10.1007/s00280-012-1963-2
Publikováno v:
The Laryngoscope. 113:1487-1493
Objectives To analyze dietary antioxidant intake for head and neck cancer patients at risk for development of second primary cancers. Study Design Prospective observational study. Methods Twenty-four patients underwent three random, unscheduled, 24-h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee6057886a7eff8bec883abbd4c229d4
https://doi.org/10.1097/00005537-200309000-00012
https://doi.org/10.1097/00005537-200309000-00012
Publikováno v:
Head & Neck. 25:274-279
Background. Human trials of alloantigen gene therapy, using the class I major histocompatibility complex (MHC) HLA-B7, have demonstrated the potential efficacy of this treatment for head and neck cancer. Its mechanism remains unclear. An immune-compe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f94cea1d88ce2a272f26c22c37af4d1e
https://doi.org/10.1002/hed.10258
https://doi.org/10.1002/hed.10258
Publikováno v:
ORL. 65:193-198
Objective:A reliable genetic marker to predict outcome for head and neck cancer is needed. In colon cancer, microsatellite instability (MSI) predicts response to therapy and improved prognosis. Colon cancer patients with MSI have a 60% improvement in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02a9285ff67eff562cd3609e6054bbe4
https://doi.org/10.1159/000073113
https://doi.org/10.1159/000073113